Synopsis
Anticipate, distinguish and manage prolonged postoperative mineral uptake after parathyroid surgery while protecting against acute symptomatic hypocalcaemia.
- Hungry-bone syndrome is sustained postoperative hypocalcaemia caused by rapid skeletal uptake of calcium, phosphate and magnesium after an abrupt fall in excessive parathyroid hormone drive.
- Risk is greatest with severe longstanding hyperparathyroid bone turnover, high alkaline phosphatase, radiological bone disease, very high preoperative PTH, vitamin D deficiency and extensive parathyroid surgery.
- The biochemical pattern often combines low calcium, low phosphate and low magnesium with a PTH concentration that is not appropriately absent; postoperative hypoparathyroidism more typically produces low calcium with high phosphate and low or inappropriately normal PTH.
- Measure adjusted calcium and PTH before discharge after surgery for primary hyperparathyroidism, as NICE recommends, but use ionised calcium when critical illness or albumin makes correction formulae unreliable.
- Correct magnesium and vitamin D status as well as calcium because magnesium depletion impairs PTH secretion and action and can make replacement appear ineffective.
- Severe symptomatic hypocalcaemia requires monitored intravenous calcium; ongoing hungry-bone losses usually need substantial, individually titrated oral calcium plus an active vitamin D analogue under specialist direction.
- Requirements can change rapidly as skeletal remineralisation slows, so an unchanged high replacement regimen can later cause hypercalcaemia or hypercalciuria.
- Discharge only with a written dose plan, early blood-test dates, symptom safety-netting and a named endocrine or surgical contact able to adjust treatment promptly.
Key red flags
Perioral or fingertip tingling, muscle aching, cramps and heightened reflexes may precede overt tetany and should trigger an immediate calcium check after surgery.
Carpopedal spasm, stridor, bronchospasm, laryngospasm, confusion or seizure indicates dangerous hypocalcaemia and requires monitored emergency treatment rather than oral replacement alone.
QT prolongation, hypotension, heart failure or ventricular arrhythmia can occur, with additional risk from digoxin exposure and coexisting potassium or magnesium disturbance.
Investigation priorities
Confirm severity and define the postoperative direction and response to replacement.
Management branches
A patient with marked primary or renal hyperparathyroidism is scheduled for parathyroid surgery.
- Identify high bone-turnover features, renal impairment, vitamin D and magnesium deficiency, previous fractures and medicines that complicate calcium interpretation or replacement.
- Agree the postoperative calcium, phosphate, magnesium and PTH schedule with endocrine, renal and surgical teams, including the monitored setting and access to intravenous calcium.
- Give the patient specific symptom education and establish a specialist-led oral calcium and vitamin D plan rather than leaving supplementation to an unreviewed routine prescription.
Calcium is clinically stable on an oral regimen and the patient can manage treatment outside hospital.
- Supply an exact written regimen, interaction and timing advice, missed-dose instructions, emergency symptoms and scheduled early laboratory checks with named result ownership.
- Reduce replacement only from serial results and specialist advice; monitor for constipation, renal stones, hypercalcaemia, hypercalciuria and an abrupt fall in requirement.
- Complete NICE postoperative calcium and PTH follow-up while adapting the frequency for ongoing hungry bone, renal disease or evidence of recurrent hyperparathyroidism.
Key medicines
Calcium gluconate 10% for acute symptomsFor acute symptomatic hypocalcaemia, the current SmPC permits 10–20 mL by slow intravenous injection or diluted infusion over 10 minutes with plasma calcium and ECG monitoring; repeat and continuing infusion decisions require the live protocol and senior review.Confirm the product because calcium gluconate and calcium chloride are not equivalent. Ensure venous patency, avoid extravasation, monitor rhythm, consider digoxin toxicity and renal impairment, and do not use a short bolus as the complete treatment for ongoing skeletal uptake.
Oral calcium with active vitamin DDose and divide the locally selected calcium preparation and calcitriol or alfacalcidol individually under endocrine or renal supervision, titrating to serial biochemistry rather than applying a fixed universal hungry-bone regimen.Check elemental calcium content, renal function, phosphate, magnesium, vitamin D, interactions and adherence. High requirements may fall suddenly; continued unchanged dosing can cause hypercalcaemia, hypercalciuria, nephrocalcinosis or calcium–phosphate deposition.